ADA Compliance for Pharmaceutical Websites

Pharmaceutical companies operate under intense regulatory oversight from the FDA, which has issued guidance recommending that drug information websites be accessible to people with disabilities. While FDA guidance is not legally binding in the same way as ADA requirements, it signals the direction of enforcement. The DOJ has targeted pharma-adjacent healthcare organizations, and plaintiff firms are increasingly filing ADA lawsuits against pharmaceutical websites that provide drug information to consumers.

Settlements in healthcare-related digital accessibility cases range from $25,000 to $250,000. The ADA Title II deadline of April 24, 2026 directly affects pharma companies that operate patient assistance programs funded by government entities or provide information through government health portals. The European Accessibility Act (EAA) adds further pressure for pharma companies serving EU markets.

Pharmaceutical websites must make complex medical information accessible without compromising accuracy:

• Drug interaction checkers with autocomplete fields and complex result matrices that screen readers cannot parse or navigate
• Prescribing information (PI) documents published as scanned PDFs without OCR text layers, making them completely invisible to assistive technology
• Side effect frequency tables and clinical study data presented in complex nested tables without proper header associations
• Medication guides using images of text for warning labels and boxed warnings that screen readers skip entirely

When a patient with a visual disability cannot access drug safety information independently, the consequences go beyond legal liability — they become a patient safety issue.

Clinical trial recruitment pages and patient assistance program applications are high-stakes accessibility touchpoints. Trial finder tools with location-based search, eligibility screening questionnaires, and enrollment forms must be fully accessible. If people with disabilities cannot find and enroll in clinical trials, this creates both an ADA violation and a bias in clinical research that the FDA increasingly scrutinizes.

Patient assistance programs (PAPs) that help uninsured or underinsured patients access medications often have complex application forms with income verification, insurance documentation upload, and multi-step approval workflows. These forms frequently use inaccessible file upload components, undescriptive error messages, and progress indicators that assistive technology cannot interpret. Making PAP applications accessible is both a compliance requirement and a moral imperative for companies whose stated mission is patient access to medication.

Run a free CompliScan scan on your public drug information pages, clinical trial finder, patient assistance portal, and HCP (healthcare professional) section to identify WCAG 2.1 AA violations. Automated tools catch 30-40% of issues, providing a critical starting point for compliance programs.

Pharmaceutical companies typically manage multiple product sites, HCP portals, and patient-facing properties. CompliScan Agency ($299/mo) provides monitoring across up to 50 domains with compliance reporting suitable for regulatory submissions. Individual product sites can use Shield Pro ($149/mo) for daily scans with AI fix suggestions. Prioritize remediation of prescribing information documents, drug interaction tools, and patient assistance application forms — these carry the highest patient safety and legal risk.